5-(3-ethyl-1H-indazol-5-yl)-1,3,4-thiadiazol-2-amine | 885222-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 5-(3-ethyl-1H-indazol-5-yl)-1,3,4-thiadiazol-2-amine
• 英文别名: 5-(3-ethyl-2H-indazol-5-yl)-1,3,4-thiadiazol-2-amine
• CAS: 885222-89-9
• 化学式: C₁₁H₁₁N₅S
• 分子量: 245.308
• InChiKey: NCPXRVZEPMJYMU-UHFFFAOYSA-N

物化性质

• 沸点：
  524.4±42.0 °C(Predicted)
• 密度：
  1.431±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(3-ethyl-1H-indazol-5-yl)-1,3,4-thiadiazol-2-amine 、 BOC-L-苯丙氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics

  摘要：

  A series of 2-aminothiadiazole of inhibitors of AKT1 is described. SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2). Moderate selectivity observed in several compounds for AKT1 versus PKA is rationalized by X-ray crystallographic analysis. Key compounds showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1. Compound 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.046
• 作为产物：
  描述：

  3-乙基-1H-吲唑-5-羧酸 、 氨基硫脲 在 polyphosphoric acid 作用下， 以 四氢呋喃 为溶剂， 生成 5-(3-ethyl-1H-indazol-5-yl)-1,3,4-thiadiazol-2-amine
  参考文献：
  名称：

  2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics

  摘要：

  A series of 2-aminothiadiazole of inhibitors of AKT1 is described. SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2). Moderate selectivity observed in several compounds for AKT1 versus PKA is rationalized by X-ray crystallographic analysis. Key compounds showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1. Compound 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.046

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• Thiadiazole compounds and methods of use
  申请人：Monenschein Holger

  公开号：US20080255145A1

  公开（公告）日：2008-10-16

  The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种对蛋白激酶B（PKB）介导的疾病有用的噻二唑化合物。本发明还涉及在治疗与异常细胞生长、癌症、炎症和代谢障碍有关的疾病状态中使用这种噻二唑化合物及其组合物的治疗用途。
• THIADIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Amgen, Inc

  公开号：EP1809282A2

  公开（公告）日：2007-07-25
• US7354944B2
  申请人：——

  公开号：US7354944B2

  公开（公告）日：2008-04-08
• US7700636B2
  申请人：——

  公开号：US7700636B2

  公开（公告）日：2010-04-20